{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T00:03:21Z","timestamp":1789603401352,"version":"build-2803163510"},"reference-count":55,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T00:00:00Z","timestamp":1782950400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100014717","name":"National Natural Science Foundation of China National Outstanding Youth Science Fund Project","doi-asserted-by":"publisher","award":["82073904"],"award-info":[{"award-number":["82073904"]}],"id":[{"id":"10.13039\/100014717","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014717","name":"National Natural Science Foundation of China National Outstanding Youth Science Fund Project","doi-asserted-by":"publisher","award":["82273961"],"award-info":[{"award-number":["82273961"]}],"id":[{"id":"10.13039\/100014717","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014717","name":"National Natural Science Foundation of China National Outstanding Youth Science Fund Project","doi-asserted-by":"publisher","award":["81872915"],"award-info":[{"award-number":["81872915"]}],"id":[{"id":"10.13039\/100014717","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017944","name":"Hainan Provincial Postdoctoral Science Foundation","doi-asserted-by":"publisher","award":["ZDKJ2021028"],"award-info":[{"award-number":["ZDKJ2021028"]}],"id":[{"id":"10.13039\/100017944","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Acta Pharmaceutica Sinica B"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.apsb.2026.07.003","type":"journal-article","created":{"date-parts":[[2026,7,5]],"date-time":"2026-07-05T15:04:58Z","timestamp":1783263898000},"page":"5884-5900","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Molecular architecture responsible for specific inhibition of oncogenic PI3K\u03b1 mutants by RLY-2608 and STX-478"],"prefix":"10.1016","volume":"16","author":[{"given":"Xiao","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanyan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-5434-1923","authenticated-orcid":false,"given":"Guanyi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9895-7094","authenticated-orcid":false,"given":"Anqi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingtong","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6550-9017","authenticated-orcid":false,"given":"Ming-Wei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.apsb.2026.07.003_bib1","doi-asserted-by":"crossref","first-page":"372","DOI":"10.3109\/07853890.2014.912836","article-title":"PI3K\/AKT signaling pathway and cancer: an updated review","volume":"46","author":"Martini","year":"2014","journal-title":"Ann Med"},{"key":"10.1016\/j.apsb.2026.07.003_bib2","doi-asserted-by":"crossref","first-page":"5497","DOI":"10.1038\/onc.2008.245","article-title":"PI3K pathway alterations in cancer: variations on a theme","volume":"27","author":"Yuan","year":"2008","journal-title":"Oncogene"},{"key":"10.1016\/j.apsb.2026.07.003_bib3","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1038\/s41574-020-0329-9","article-title":"Insulin-PI3K signalling: an evolutionarily insulated metabolic driver of cancer","volume":"16","author":"Hopkins","year":"2020","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.apsb.2026.07.003_bib4","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.cell.2017.07.029","article-title":"The PI3K pathway in human disease","volume":"170","author":"Fruman","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.apsb.2026.07.003_bib5","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s12943-019-0954-x","article-title":"Targeting PI3K in cancer: mechanisms and advances in clinical trials","volume":"18","author":"Yang","year":"2019","journal-title":"Mol Cancer"},{"key":"10.1016\/j.apsb.2026.07.003_bib6","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1038\/s43018-021-00218-4","article-title":"The present and future of PI3K inhibitors for cancer therapy","volume":"2","author":"Castel","year":"2021","journal-title":"Nat Cancer"},{"key":"10.1016\/j.apsb.2026.07.003_bib7","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/nrclinonc.2018.28","article-title":"Targeting the PI3K pathway in cancer: are we making headway?.","volume":"15","author":"Janku","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.apsb.2026.07.003_bib8","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1038\/s41571-022-00633-1","article-title":"At a crossroads: how to translate the roles of PI3K in oncogenic and metabolic signalling into improvements in cancer therapy","volume":"19","author":"Vasan","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.apsb.2026.07.003_bib9","doi-asserted-by":"crossref","first-page":"2652","DOI":"10.1073\/pnas.0712169105","article-title":"Helical domain and kinase domain mutations in p110\u03b1 of phosphatidylinositol 3-kinase induce gain of function by different mechanisms","volume":"105","author":"Zhao","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.apsb.2026.07.003_bib10","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2109327118","article-title":"Cryo-EM structures of PI3K\u03b1 reveal conformational changes during inhibition and activation","volume":"118","author":"Liu","year":"2021","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.apsb.2026.07.003_bib11","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1158\/2159-8290.CD-23-0704","article-title":"Allosteric PI3K\u03b1 inhibition overcomes on-target resistance to orthosteric inhibitors mediated by secondary PIK3CA mutations","volume":"14","author":"Varkaris","year":"2024","journal-title":"Cancer Discov"},{"key":"10.1016\/j.apsb.2026.07.003_bib12","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.ccr.2005.05.014","article-title":"Mutant PIK3CA promotes cell growth and invasion of human cancer cells","volume":"7","author":"Samuels","year":"2005","journal-title":"Cancer Cell"},{"key":"10.1016\/j.apsb.2026.07.003_bib13","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1038\/s41416-023-02221-1","article-title":"The emerging role of PI3K inhibitors for solid tumour treatment and beyond","volume":"128","author":"Belli","year":"2023","journal-title":"Br J Cancer"},{"key":"10.1016\/j.apsb.2026.07.003_bib14","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1186\/s12943-024-02072-1","article-title":"Targeting PI3K family with small-molecule inhibitors in cancer therapy: current clinical status and future directions","volume":"23","author":"Li","year":"2024","journal-title":"Mol Cancer"},{"key":"10.1016\/j.apsb.2026.07.003_bib15","doi-asserted-by":"crossref","first-page":"3464","DOI":"10.3390\/ijms22073464","article-title":"PI3K inhibitors in cancer: clinical implications and adverse effects","volume":"22","author":"Mishra","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.apsb.2026.07.003_bib16","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.bbcan.2019.03.003","article-title":"Targeting PI3K signaling in cancer: challenges and advances","volume":"1871","author":"De Santis","year":"2019","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"10.1016\/j.apsb.2026.07.003_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2019.111718","article-title":"Phosphatidylinositol 3 kinase (PI3K) inhibitors as new weapon to combat cancer","volume":"183","author":"Elmenier","year":"2019","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.apsb.2026.07.003_bib18","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1158\/2159-8290.CD-23-0944","article-title":"Discovery and clinical proof-of-concept of RLY-2608, a first-in-class mutant-selective allosteric PI3K\u03b1 inhibitor that decouples antitumor activity from hyperinsulinemia","volume":"14","author":"Varkaris","year":"2024","journal-title":"Cancer Discov"},{"key":"10.1016\/j.apsb.2026.07.003_bib19","article-title":"Oncogenic activation of PIK3CA in cancers: emerging targeted therapies in precision oncology","volume":"12","author":"Wang","year":"2025","journal-title":"Genes Dis"},{"key":"10.1016\/j.apsb.2026.07.003_bib20","doi-asserted-by":"crossref","first-page":"2432","DOI":"10.1158\/2159-8290.CD-23-0396","article-title":"STX-478, a mutant-selective, allosteric PI3K\u03b1 inhibitor spares metabolic dysfunction and improves therapeutic response in PI3K\u03b1-mutant xenografts","volume":"13","author":"Buckbinder","year":"2023","journal-title":"Cancer Discov"},{"key":"10.1016\/j.apsb.2026.07.003_bib21","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2215621119","article-title":"Cryo-EM structures of cancer-specific helical and kinase domain mutations of PI3K\u03b1","volume":"119","author":"Liu","year":"2022","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.apsb.2026.07.003_bib22","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1038\/nmeth.4193","article-title":"MotionCor2: anisotropic correction of beam-induced motion for improved cryo-electron microscopy","volume":"14","author":"Zheng","year":"2017","journal-title":"Nat Methods"},{"key":"10.1016\/j.apsb.2026.07.003_bib23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jsb.2015.11.003","article-title":"Gctf: real-time CTF determination and correction","volume":"193","author":"Zhang","year":"2016","journal-title":"J Struct Biol"},{"key":"10.1016\/j.apsb.2026.07.003_bib24","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1107\/S0907444909029436","article-title":"Electronic Ligand Builder and Optimization Workbench (eLBOW): a tool for ligand coordinate and restraint generation","volume":"65","author":"Moriarty","year":"2009","journal-title":"Acta Crystallogr D Biol Crystallogr"},{"key":"10.1016\/j.apsb.2026.07.003_bib25","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1107\/S0907444906017161","article-title":"Automated ligand fitting by core-fragment fitting and extension into density","volume":"62","author":"Terwilliger","year":"2006","journal-title":"Acta Crystallogr D Biol Crystallogr"},{"key":"10.1016\/j.apsb.2026.07.003_bib26","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1002\/jcc.20084","article-title":"UCSF Chimera\u2014A visualization system for exploratory research and analysis","volume":"25","author":"Pettersen","year":"2004","journal-title":"J Comput Chem"},{"key":"10.1016\/j.apsb.2026.07.003_bib27","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1002\/pro.3943","article-title":"UCSF ChimeraX: structure visualization for researchers, educators, and developers","volume":"30","author":"Pettersen","year":"2021","journal-title":"Protein Sci"},{"key":"10.1016\/j.apsb.2026.07.003_bib28","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.softx.2015.06.001","article-title":"GROMACS: high performance molecular simulations through multi-level parallelism from laptops to supercomputers","volume":"1-2","author":"Abraham","year":"2015","journal-title":"SoftwareX"},{"key":"10.1016\/j.apsb.2026.07.003_bib29","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1002\/jcc.20945","article-title":"CHARMM-GUI: a web-based graphical user interface for CHARMM","volume":"29","author":"Jo","year":"2008","journal-title":"J Comput Chem"},{"key":"10.1016\/j.apsb.2026.07.003_bib30","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/nmeth.4067","article-title":"CHARMM36m: an improved force field for folded and intrinsically disordered proteins","volume":"14","author":"Huang","year":"2017","journal-title":"Nat Methods"},{"key":"10.1016\/j.apsb.2026.07.003_bib31","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1002\/jcc.21367","article-title":"CHARMM general force field: a force field for drug-like molecules compatible with the CHARMM all-atom additive biological force fields","volume":"31","author":"Vanommeslaeghe","year":"2010","journal-title":"J Comput Chem"},{"key":"10.1016\/j.apsb.2026.07.003_bib32","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1021\/ct700200b","article-title":"P-LINCS: a parallel linear constraint solver for molecular simulation","volume":"4","author":"Hess","year":"2008","journal-title":"J Chem Theory Comput"},{"key":"10.1016\/j.apsb.2026.07.003_bib33","doi-asserted-by":"crossref","DOI":"10.1063\/1.2408420","article-title":"Canonical sampling through velocity rescaling","volume":"126","author":"Bussi","year":"2007","journal-title":"J Chem Phys"},{"key":"10.1016\/j.apsb.2026.07.003_bib34","doi-asserted-by":"crossref","first-page":"6541","DOI":"10.1103\/PhysRevA.46.6541","article-title":"Constant-pressure molecular-dynamics simulations of the crystal-smectic transition in systems of soft parallel spherocylinders","volume":"46","author":"Aoki","year":"1992","journal-title":"Phys Rev A"},{"key":"10.1016\/j.apsb.2026.07.003_bib35","doi-asserted-by":"crossref","first-page":"189","DOI":"10.12688\/f1000research.7931.1","article-title":"FreeSASA: an open source C library for solvent accessible surface area calculations","volume":"5","author":"Mitternacht","year":"2016","journal-title":"F1000Research"},{"key":"10.1016\/j.apsb.2026.07.003_bib36","article-title":"Deeptime: a Python library for machine learning dynamical models from time series data","volume":"3","author":"Hoffmann","year":"2022","journal-title":"Mach Learn: Sci Technol"},{"key":"10.1016\/j.apsb.2026.07.003_bib37","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pcbi.1003895","article-title":"Investigating the structure and dynamics of the PIK3CA wild-type and H1047R oncogenic mutant","volume":"10","author":"Gkeka","year":"2014","journal-title":"PLoS Comput Biol"},{"key":"10.1016\/j.apsb.2026.07.003_bib38","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/s41586-023-05972-2","article-title":"A small-molecule PI3K\u03b1 activator for cardioprotection and neuroregeneration","volume":"618","author":"Gong","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.apsb.2026.07.003_bib39","doi-asserted-by":"crossref","first-page":"13541","DOI":"10.1074\/jbc.M116.772426","article-title":"Kinetic and structural analyses reveal residues in phosphoinositide 3-kinase \u03b1 that are critical for catalysis and substrate recognition","volume":"292","author":"Maheshwari","year":"2017","journal-title":"J Biol Chem"},{"key":"10.1016\/j.apsb.2026.07.003_bib40","doi-asserted-by":"crossref","first-page":"77","DOI":"10.3390\/cancers17010077","article-title":"Molecular basis of oncogenic PI3K proteins","volume":"17","author":"Sheng","year":"2024","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.apsb.2026.07.003_bib41","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1038\/s41421-025-00833-w","article-title":"Molecular mechanisms of PI3K\u03b1 activation by small-molecule activator 1938 and cancer-specific mutation H1047R","volume":"11","author":"Liu","year":"2025","journal-title":"Cell Discov"},{"key":"10.1016\/j.apsb.2026.07.003_bib42","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/s42004-026-01906-x","article-title":"Oncogenic PI3K\u03b1 variants reveal graded conformational spectrum with mutation-specific cryptic pockets","volume":"9","author":"Jang","year":"2026","journal-title":"Commun Chem"},{"key":"10.1016\/j.apsb.2026.07.003_bib43","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1126\/science.1150799","article-title":"The structure of a human p110 \u03b1\/p85 \u03b1 complex elucidates the effects of oncogenic PI3K\u03b1 mutations","volume":"318","author":"Huang","year":"2007","journal-title":"Science"},{"key":"10.1016\/j.apsb.2026.07.003_bib44","doi-asserted-by":"crossref","first-page":"3655","DOI":"10.1038\/onc.2011.532","article-title":"Regulation of lipid binding underlies the activation mechanism of class IA PI3-kinases","volume":"31","author":"Hon","year":"2012","journal-title":"Oncogene"},{"key":"10.1016\/j.apsb.2026.07.003_bib45","doi-asserted-by":"crossref","first-page":"5198","DOI":"10.18632\/oncotarget.2263","article-title":"Structural basis of nSH2 regulation and lipid binding in PI3K\u03b1","volume":"5","author":"Miller","year":"2014","journal-title":"Oncotarget"},{"key":"10.1016\/j.apsb.2026.07.003_bib46","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/s41467-023-35789-6","article-title":"Oncogenic mutations of PIK3CA lead to increased membrane recruitment driven by reorientation of the ABD, p85 and C-terminus","volume":"14","author":"Jenkins","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.apsb.2026.07.003_bib47","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1042\/BCJ20240479","article-title":"ATP-competitive inhibitors of PI3K enzymes demonstrate an isoform selective dual action by controlling membrane binding","volume":"481","author":"Gong","year":"2024","journal-title":"Biochem J"},{"key":"10.1016\/j.apsb.2026.07.003_bib48","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1042\/BCJ20180022","article-title":"Understanding phosphoinositides: rare, dynamic, and essential membrane phospholipids","volume":"476","author":"Dickson","year":"2019","journal-title":"Biochem J"},{"key":"10.1016\/j.apsb.2026.07.003_bib49","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2024.114119","article-title":"A p85 isoform switch enhances PI3K activation on endosomes by a MAP4- and PI3P-dependent mechanism","volume":"43","author":"Thapa","year":"2024","journal-title":"Cell Rep"},{"key":"10.1016\/j.apsb.2026.07.003_bib50","doi-asserted-by":"crossref","first-page":"16996","DOI":"10.1073\/pnas.0908444106","article-title":"A frequent kinase domain mutation that changes the interaction between PI3K\u03b1 and the membrane","volume":"106","author":"Mandelker","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.apsb.2026.07.003_bib51","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2023.113535","article-title":"Epinephrine inhibits PI3K\u03b1 via the Hippo kinases","volume":"42","author":"Lin","year":"2023","journal-title":"Cell Rep"},{"key":"10.1016\/j.apsb.2026.07.003_bib52","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s13058-020-01284-9","article-title":"Frequency and spectrum of PIK3CA somatic mutations in breast cancer","volume":"22","author":"Mart\u00ednez-S\u00e1ez","year":"2020","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.apsb.2026.07.003_bib53","doi-asserted-by":"crossref","first-page":"5855","DOI":"10.1039\/D0SC01676D","article-title":"PI3K inhibitors: review and new strategies","volume":"11","author":"Zhang","year":"2020","journal-title":"Chem Sci"},{"key":"10.1016\/j.apsb.2026.07.003_bib54","doi-asserted-by":"crossref","DOI":"10.1016\/j.str.2024.03.007","article-title":"Cryo-EM structures reveal two allosteric inhibition modes of PI3K\u03b1(H1047R) involving a re-shaping of the activation loop","volume":"32","author":"Huang","year":"2024","journal-title":"Structure"},{"key":"10.1016\/j.apsb.2026.07.003_bib55","doi-asserted-by":"crossref","first-page":"4936","DOI":"10.1021\/acs.jmedchem.4c00078","article-title":"Discovery of pyridopyrimidinones that selectively inhibit the H1047R PI3K\u03b1 mutant protein","volume":"67","author":"Ketcham","year":"2024","journal-title":"J Med Chem"}],"container-title":["Acta Pharmaceutica Sinica B"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211383526004259?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211383526004259?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T23:18:51Z","timestamp":1789600731000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211383526004259"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":55,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S2211383526004259"],"URL":"https:\/\/doi.org\/10.1016\/j.apsb.2026.07.003","relation":{},"ISSN":["2211-3835"],"issn-type":[{"value":"2211-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Molecular architecture responsible for specific inhibition of oncogenic PI3K\u03b1 mutants by RLY-2608 and STX-478","name":"articletitle","label":"Article Title"},{"value":"Acta Pharmaceutica Sinica B","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.apsb.2026.07.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V. on behalf of Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences.","name":"copyright","label":"Copyright"}]}}